Journey Medical (DERM) Receives New Analyst Coverage with ‘Buy’ Rating and $13 PT

Journey Medical (DERM) received new analyst coverage from HC Wainwright & Co with a ‘Buy’ rating and a $13 price target. This follows recent positive sentiment from other analysts, including Lake Street and B. Riley Securities. The average analyst price target is $11.50, with a high estimate of $13 and a low estimate of $10. The estimated GF Value for Journey Medical is $4.13, suggesting a downside of 44.71% from the current price.

Journey Medical Corporation (DERM) has received new analyst coverage from HC Wainwright & Co, with a ‘Buy’ rating and a $13 price target. This follows recent positive sentiment from other analysts, including Lake Street and B. Riley Securities. The average analyst price target is $11.50, with a high estimate of $13 and a low estimate of $10. The estimated GF Value for Journey Medical is $4.13, suggesting a downside of 44.71% from the current price.

The company, focused on the development and commercialization of pharmaceutical products for dermatological conditions, has a portfolio of nine branded and generic drugs marketed in the United States. These include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, Luxamend, sulconazole nitrate cream and solution, and doxycycline hyclate immediate release 50mg tablets [1].

The positive analyst sentiment comes amidst regulatory challenges faced by B. Riley Financial (Nasdaq: RILY), which received a delinquency notification from Nasdaq for failing to comply with Listing Rule 5250(c)(1) due to delayed filing of its Q2 2025 Form 10-Q [2]. The company has until September 29, 2025 to file multiple delinquent reports, including its 2024 Form 10-K and Q1-Q2 2025 Form 10-Qs. While this regulatory issue does not immediately impact Journey Medical’s operations, it adds a layer of uncertainty to the broader market.

Investors should monitor these developments closely, as they may influence the overall market perception and institutional investment eligibility. However, the positive analyst ratings for Journey Medical suggest that the company’s prospects are seen favorably by the financial community.

References:

[1] https://www.marketscreener.com/news/hc-wainwright-initiates-journey-medical-at-buy-with-13-price-target-ce7c50d8d98ff224

[2] https://www.stocktitan.net/news/RILY/b-riley-financial-announces-notification-of-delinquency-with-k6il1llypz9e.html